COVID-19 : India’s Doubling Rate Improves
Guidelines For Performing Minimal Access Surgeries During COVID-19 Pandemic By Association of Minimal Access Surgeons of India
(Refresh the page or download this document incase the PDF doesn’t load properly)
Guidelines to be Followed on Detection of Suspect or Confirmed COVID-19 Case in a Non-COVID Health Facility
(Refresh the page or download this document incase the PDF doesn’t load properly)
Pre-Op Hormonal Theraphy Beneficial in DCIS Treatment
First-of-its-kind findings suggest that hormonal therapy could be the primary treatment instead of surgery for women who are diagnosed with a precursor of breast cancer, ductal carcinoma in situ (DCIS).
New results show that pre-operative endocrine therapy produced measurable radiographic changes in a cohort of postmenopausal women with estrogen receptor (ER)–positive disease. Additionally, 15% had pathologic complete responses, which were assessed after surgery as part of the study design.
The study was published on March 3 in the Journal of Clinical Oncology.
Before the current results, the benefit of endocrine therapy in the absence of surgery for DCIS has been “largely unknown,” say the authors, led by Shelley Hwang, MD, of Duke University, Durham, North Carolina.
You must be logged in to post a comment.